Abstract
Background Adjunct intra-arterial thrombolysis has been shown to potentially improve clinical outcomes in patients with large vessel occlusion (LVO) stroke who have undergone successful endovascular thrombectomy (EVT). Tenecteplase, known for its enhanced fibrin specificity and extended activity duration, may be a better choice than alteplase for intra-arterial thrombolysis. However, the optimal dose, safety and efficacy of intra-arterial tenecteplase remain unclear.
Objective To evaluate the optimal dose, safety and efficacy of adjunctive intra-arterial tenecteplase following successful EVT in LVO patients.
Methods and design This study is a two-part, phase Ib/IIa, multicenter, open-label, 14+8 dose-escalation (Part I) and dose-expansion (Part II) trial conducted in China involving patients LVO patients who achieved successful EVT (defined as the expanded Thrombolysis in Cerebral Infarction [eTICI] grade of 2b50 or higher) within 24 hours of last known well. In Part Ib, the dose escalation will be conducted in up to four tiers of 14+8 patients, starting at 0.03125 mg/kg, to a planned maximum of 0.1875mg/kg, and the primary outcome is symptomatic intracranial hemorrhage within 24 hours. In Part IIa, 157 patients will be randomized among two selected safe doses and a placebo, and the primary outcome will be the proportion of patients with nondisabled outcome (modified Rankin Scale score of 0 to 1) at 90 days.
Discussions This pivotal trial will provide important data on adjunctive intra-arterial tenecteplase following successful EVT in patients with acute ischemic stroke due to LVO and may support advance of treatment standards.
Trial registry number ChiCTR2300073787 and ChiCTR2400080624 (www.chictr.org.cn).
Competing Interest Statement
The author(s) declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: JLS reports consulting fees for advising on rigorous and safe clinical trial design and conduct from Biogen, Boehringer Ingelheim, Genentech, Johnson & Johnson, Phenox, Phillips, Rapid Medical, and Roche. TNN discloses Associate Editor of Stroke, advisory board of Aruna Bio and Brainomix. RGN reports consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Philips, Hybernia, Hyperfine, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, Synchron, and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, CrestecBio Inc., Euphrates Vascular, Inc., Vesalio, Viz-AI, RapidPulse, and Perfuze. RGN is one of the Principal Investigators of the ENDOLOW trial. Funding for this project is provided by Cerenovus. RGN is the Principal Investigator of the DUSK trial. Funding for this project is provided by Stryker Neurovascular. RGN is an investor in Viz-AI, Perfuze, Cerebrotech, Reist/Q Apel Medical, Truvic, Tulavi Therapeutics, Vastrax, Piraeus Medical, Brain4Care, Quantanosis AI, and Viseon. T. Nguyen reports Associate Editor of Stroke; advisory board of Brainomix, Aruna Bio; speaker for Genentech and Kaneka. Other author(s) declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Clinical Trial
ChiCTR2300073787 and ChiCTR2400080624 (www.chictr.org.cn).
Funding Statement
The project was supported by the Key Project of Chongqing Science (2023ZDXM025), National Natural Science Foundation of China (No. 82425021), and Health Joint Medical Research Project and the Major Project of Clinical Research Incubation at the First Affiliated Hospital of Army Medical University (2023IITZD01).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol was approved by the Ethics Committee of the First Affiliated Hospital of the Army Medical University and all participating centers.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data from the DATE trial are currently not publicly available but are planned to be made available in the future. The timing of this availability and criteria for gaining access have not been determined. Requests regarding data access should be made to Professor Zhenhua Zhou.
